Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Lilly research into antiobesity proteins continues

Dec. 2, 1996

Avigen reports successful gene therapy with EPO

Nov. 29, 1996

Harvard Scientific seeks to proceed with clinical trials on erectile dysfunction Rx

Nov. 29, 1996

Animal model for testing osteoporotic therapies available for licensing

Nov. 29, 1996

rhBMP-2 cleared for limited clinical trial for spine fusion

Nov. 28, 1996

FDA clears treatment for bulimia

Nov. 27, 1996

Water-soluble fiber introduced in first market for high cholesterol

Nov. 27, 1996

Agreement reached for atorvastatin development in Japan

Nov. 27, 1996

Uropontin and MAbs with potential in osteoporosis available for licensing

Nov. 26, 1996

Somatogen reports plans for Optro

Nov. 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 14, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...